Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Invested Capital (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Invested Capital for 15 consecutive years, with $638.0 million as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital fell 6.63% year-over-year to $638.0 million; the TTM value through Mar 2026 reached $638.0 million, down 6.63%, while the annual FY2025 figure was $647.8 million, 4.68% down from the prior year.
  • Invested Capital hit $638.0 million in Q1 2026 for Corcept Therapeutics, down from $647.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $683.3 million in Q1 2025 and bottomed at $407.8 million in Q1 2022.
  • Average Invested Capital over 5 years is $555.5 million, with a median of $547.9 million recorded in 2024.
  • Year-over-year, Invested Capital decreased 20.16% in 2022 and then surged 41.42% in 2024.
  • Corcept Therapeutics' Invested Capital stood at $501.8 million in 2022, then grew by 0.97% to $506.7 million in 2023, then soared by 34.12% to $679.6 million in 2024, then decreased by 4.68% to $647.8 million in 2025, then fell by 1.52% to $638.0 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $638.0 million, $647.8 million, and $631.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.